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ABSTRACT 
Multiple Sclerosis (MS) is a chronic inflammatory and neurodegenerative disease driven by 
autoreactive CD4+ T cells. Disease etiology is mediated by a strong interplay between genetic 
and environmental factors implying a role for epigenetic mechanisms. Epigenetics is defined 
as the study of mechanisms, such as DNA methylation, histone modifications and non-coding 
RNAs, that result in changes of gene expression without altering the underlying genetic code. 
Genomic imprinting, one of the most-studied epigenetic marking processes, causes a gene to 
be expressed only from the maternally or paternally inherited chromosome.  
In this thesis we investigate the contribution of epigenetic mechanisms to the etiology and 
pathogenesis of MS and its animal model, experimental autoimmune encephalomyelitis 
(EAE). 
We investigated the impact of parent-of-origin, in particular genomic imprinting, using two 
large populations of reciprocal backcross rats and identified that epigenetic mechanisms play 
a role in EAE inheritance and pathogenesis. Using a transgenic mouse model, we discovered 
that the imprinted Dlk1 gene impacts the underlying immune responses in EAE. Further 
discovery of imprinted genes, using RNA sequencing in adult reciprocal hybrid rats, provided 
additional insights into the underlying mechanisms of how imprinted genes could interfere 
with the immune response in EAE by modulating CD4+ T cell function. 
Utilizing a genome-wide approach to identify DNA methylation changes between MS 
patients and controls in CD4+ T cells and monocytes revealed how DNA methylation as an 
epigenetic mark can impact the function of CD4+ T cells in MS. We identified that DNA 
methylation acts as a mediator of the major MS risk factor, the HLA-DRB1 gene, to impact 
expression of the HLA class II molecules that present antigens to CD4+ T cells. DNA 
methylation further affected CD4+ T cells directly through changed epigenetic marking of a 
microRNA, miR-21, impacting miR-21 expression and its target genes. 
Our findings collectively underline the importance of integrating multiple layers of gene 
regulation to identify novel mechanisms involved in the etiology and pathogenesis of 
complex diseases like MS. This will in turn open up for novel therapeutic approaches based 
on targeting dysregulated epigenomes in human disease.  
.
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1 INTRODUCTION 
 
1.1 Immune System 
The immune system is a defense system that protects against disease by recognizing and 
fighting a variety of foreign agents while distinguishing them from the body's own healthy 
tissue. The immune system consists of two parts, the innate and the adaptive immune system. 
Whereas the innate immune system comprises immune cells and mechanisms (such as 
neutrophils, monocytes, macrophages, complement system, cytokines and acute phase 
proteins) that allow for a rapid but non-specific response, the adaptive immune system is 
highly specific for a particular antigen that triggers a response of lymphocytes and it takes 
days or even weeks to develop1. There are two broad classes of the adaptive immune 
responses, antibody and cell-mediated responses that are carried out by B and T 
lymphocytes, respectively.  
In the cell-mediated adaptive immune response, cytotoxic CD8+ T cells attack infected or 
damaged cells directly, while ‘helper’ CD4+ T cells regulate the adaptive immune response 
by directing other immune cells to perform various tasks. To exert their effector functions, 
naïve T cells need to be activated by antigen presenting cells (APCs) such as dendritic cells, 
monocytes, macrophages and B cells that express major histocompatibility complex (MHC) 
molecules that present the antigen to T cells and at the same time provide co-stimulatory 
signals. CD4+ and CD8+ T cells express T cell receptors (TCR) that recognize antigens 
presented by MHC class II molecules and MHC class I molecules, respectively1.  
Several types of helper CD4+ T cell lineages, including T helper (Th) 1, Th2, Th17 and 
regulatory T cells (Treg), can be induced depending on the interaction with APCs and the 
type of cytokines they are exposed to. The subsets are characterized by the cytokines they 
produce and functional differences that include the attraction of cells of the innate immune 
system1. 
Malfunctioning of the immune system can cause pathological conditions such as 
autoimmune diseases in which the immune system fails to distinguish between self and non-
self and starts attacking body's own healthy tissue.  
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1.2 Multiple Sclerosis 
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS) affecting mostly young adults, especially women2. The disease, 
depending on which area of the CNS is affected can display a variety of symptoms with the 
most common being sensory loss, visual disturbance, motor weakness and impaired 
balance2. Most MS patients initially present with the relapsing-remitting form of MS (RR-
MS), which is characterized by episodes of active disease (relapse) and periods of clinical 
inactivity (remission). Within 20 years from diagnosis, a majority of RR-MS patients will 
convert to a secondary-progressive form (SP-MS) characterized by a continuous worsening 
with or without overlaid clinical relapses. In 10% of patients the disease is progressive from 
the onset and it is classified as a primary-progressive MS (PP-MS)2. 
Accurate diagnosis based on clinical symptoms, accessed by the expanded disability status 
scale (EDSS)3, and magnetic resonance imaging (MRI) findings is essential to allow for early 
interference with the disease course4.  
1.2.1 Treatment 
Over the last 20 years the approval of novel disease modifying drugs (DMDs) has led to the 
revolution of the therapeutic field in MS. With the release of oral DMDs there is now actually 
a choice to injectable DMDs when considering first line treatments.  
Recombinant interferon beta (Rebif, Avonex) was the first drug approved for RR-MS in 
19935. It mediates an anti-inflammatory immune response and needs to be administered by 
self-injections every two weeks. Non-transient side effects observed following interferon beta 
treatment were irritations at the sites of injection. However, some patients develop 
neutralizing antibodies against the treatment6. With the approval of natalizumab as a second 
line treatment in 20067 a good choice seemed to be available for patients where first line 
treatments failed. As a humanized monoclonal antibody that binds to alpha-4 integrin of very 
late antigen 4 (VLA4), a surface marker present on immune cells, natalizumab prevented 
leucocytes from migrating across the blood-brain-barrier (BBB)7. Unfortunately, patients 
may develop severe side effects namely progressive multifocal leukoencephalopathy, a 
potentially lethal opportunistic brain infection caused by the JC virus8.  
The first oral drug developed and released was Fingolimod (Gilenya). Fingolimod targets the 
sphingosine 1 phosphate receptor (S1PR1) and its main mechanism is the sequestration of 
lymphocytes in the lymph nodes due to S1PR1 block9. Side effects depend on the distribution 
of the receptor, which can be also found in heart, retina, lung and liver, and can in the worst 
case lead to heart block10.  
In addition to the above described DMDs several monoclonal antibodies targeting the CD20 
antigen on B cells have emerged on the market, namely rituximab, ocrelizumab and 
ofatumumab11. Following the treatment with rituximab, B cells are depleted and decreased 
levels of cytokines and T cells can be observed in the CSF13. Further, the antigen presentation 
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and co-stimulation ability of B cells is impaired after CD20 treatment14. No severe side 
effects have been observed. 
The wide range of treatments available for the relapsing-remitting form of MS, allows 
clinicians nowadays a more personalized treatment approach, to balance risks against benefits 
of different treatments for every single patient15. However, all effective treatments target the 
immune system in a broad manner. Despite the expanding range of treatments for patients 
displaying a relapsing-remitting disease course, treatment of the progressive forms of MS still 
remains a challenge and further investigations are needed. 
1.2.2 Pathogenesis 
MS is considered to be an autoimmune disease that is driven by CD4+ T cells. This 
hypothesis originates from its similarities in pathogenesis with the animal model of MS, 
experimental autoimmune encephalomyelitis (EAE) that is known to be driven by myelin 
specific T cells (described in more detail below). These myelin autoreactive T cells have 
been found in MS patients but also in healthy controls with no differences in frequencies. 
However, autoreactive T cells in MS patients were observed to be more activated compared 
to the T cells found in controls106. Moreover, genetic studies have identified Human 
Leukocyte Antigen (HLA) class II alleles that present antigen to CD4+ T cells as the major 
risk alleles for developing MS18,29. 
The exact mechanism how this activation of CD4+ T cells in the periphery takes place 
remains still poorly understood and needs to be further investigated. However, the current 
opinion in the field suggests mechanisms like molecular mimicry where T cells generated 
against a foreign antigen cross-react with self-antigens with a similar sequence or that T 
cells become activated due to myelin antigens that are constantly present in the peripheral 
lymph nodes106.  
Activated CD4+ T cells together with activated B cells and monocytes enter the CNS across 
the BBB. A crucial mechanism throughout this migration is the interaction between the 
VLA4 adhesion molecule on leucocytes and Vcam1 on endothelial cells, which allows for 
the leucocytes to overcome the immune privileged BBB. The importance of this step is 
further underlined by the observation that the migration is inhibited after antibodies against 
VLA4 have been administered106.  
In the CNS, CD4+ T cells become reactivated by APCs presenting their target antigen and 
start to differentiate into their various helper subsets, which exert different effector 
functions. Together with macrophages and microglia, they secrete proinflammatory 
cytokines, e.g. IL-17 and IFNγ that trigger the axonal demyelination process by attracting 
further innate and adaptive immune cells106. 
Beside CD4+ T cells there is also emerging evidence for CD8+ T cells to be involved in MS 
pathogenesis mediating axonal damage by the secretion of cytokines and cell contact 
mediated lysis. CD8+ T cells are more prominent in MS lesions than CD4+ T cells17 and 
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genetic studies have identified HLA class I alleles that present antigen to CD8+ T cells as 
risk alleles18.  
Further clonal expanded B cells and oligoclonal bands in the CSF of MS patients and 
antibodies directly targeting the axonal myelin sheaths imply also a crucial role for B cells 
in MS pathogenesis. These findings are further strengthened by the successful treatment 
with disease modifying drugs that target the CD20 antigen on B cells106.   
1.2.3 Experimental Autoimmune Encephalomyelitis 
To gain insights into the immune responses underlying MS, animal models are essential since 
the reactions in the CNS tissue are difficult to study in humans. The most commonly used 
animal model for MS is EAE19.   
In EAE, immunization with CNS antigen in Freud´s adjuvant results in the generation of 
pathogenic CD4+ T cells, mainly of the Th1 and Th17 type, in peripheral lymphoid organs16. 
Pathogenic CD4+ T cells migrate to the CNS where they become reactivated by macrophages, 
dendritic cells and B cells presenting the autoantigen. Reactivated CD4+ T cells start to 
secrete the cytokines such as IL-17, IFNγ, tumor necrosis factor (TNF) and granulocyte 
macrophage – colony stimulating factor (GM-CSF). Secretion of IL-17 leads to the further 
release of cytokines, chemokines and metalloproteases by local tissue cells mediating the 
further breakdown of the BBB and attraction of monocytes and neutrophils21. In addition to 
IL-17, GM-CSF also recruits neutrophils to the site of inflammation and is implied to 
influence monocytes and their impact on Th differentiation21. Further, IFNγ and TNF 
stimulate myeloid effector cells such as inflammatory monocytes, macrophages and 
neutrophils and lead to the damage of myelin by reactive oxygen species (ROS)21. In the 
peripheral lymph nodes or in the CNS, activated B cells that have become antibody-secreting 
plasma cells or plasma blasts may also release myelin targeting antibodies21. The ability to 
induce MS-like pathology by adoptive transfer of CD4+ T cells to naïve recipients further 
supports an important role of CD4+ T cells in disease pathology20. 
EAE can be induced and studied in a variety of animal species from rodents to non-human 
primates19. One of the most commonly used CNS antigens is a myelin oligodendrocyte 
glycoprotein (MOG), which is a minor component of the myelin but expressed on the outer 
layer and capable of eliciting both antibody and cell-mediated immune response. 
Immunization of the C57BL/6 mouse strain with extracellular portion of recombinant MOG 
(rMOG) in complete Freud´s adjuvant, containing Mycobacterium tuberculosis, induces EAE 
with a progressive course that resembles human disease19. The model requires additional 
Bordetella pertussis toxin injections that are known to further permeabilize the BBB22. 
Immunization of the DA rat strain with rMOG in incomplete Freud´s adjuvant results in a 
relapsing-remitting form of EAE that shares numerous features with MS23.  
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Despite differences compared to the human counterpart, several approved therapies for MS 
have been developed in EAE, demonstrating its utility when appropriately applied and 
interpreted. 
1.2.4 Risk factors for Multiple Sclerosis 
A growing body of evidence suggests that MS results from an interplay between genes and 
environmental factors. Evidence for a family aggregation of MS was provided by the 
observation that first degree relatives have a greater risk of developing MS than the rest of 
the population implying genetic factors in the pathogenesis of MS25,26. Further proof for an 
involvement of genetics came from studies conducted in adoptees and twins. Adoptees with 
MS and individuals having affected adoptive family members do not differ in their risk to 
develop MS from the rest of the population27. Monozygotic twins show a higher 
concordance rate for MS compared to dizygotic twin pairs26,28. The single most prominent 
risk for MS maps to the HLA locus and it associates, more specifically, with the HLA-
DRB1*15:01 allele18. The underlying mechanism is likely associated with the binding and 
presentation of antigens to CD4+ T cells by the HLA class II molecules. Beside the HLA 
locus more than 100 risk loci have been established to associate with MS29. Contrary to the 
HLA locus non-HLA risk loci exert only modest individual effects but in regards to their 
biological functions point to immune related functions such as lymphocyte proliferation and 
Th differentiation18. However, both the rather low familial recurrence rate and a 
concordance rate of at best only 25% in monozygotic twins indicate the involvement of 
other factors in the development of disease.   
Environmental factors that most consistently associate with the risk of developing MS 
include Epstein-Barr virus (EBV) infection, lack of vitamin D/sun exposure and cigarette 
smoking30. Individuals having encountered an EBV infection during their lifetime displayed 
a higher risk to develop MS compared to individuals that had not encountered the virus31. 
In addition, risk of MS is also known to be associated with the lack of vitamin D/sun 
exposure32,33. Studies showed that females who received vitamin D supplement displayed a 
lower risk to develop disease than females who did not get the supplement 34. In 2009, 
Hedström et al. provided convincing evidence for smoking being an important 
environmental factor in the development of MS disease by showing that MS risk was 50% 
higher in ever smokers when compared to never smokers35.  
Interestingly, a strong gene-environment interaction has been demonstrated for smoking 
and the HLA-DRB1*15:01 risk haplotype. Individuals carrying the risk allele that also had a 
history of tobacco smoking displayed a 14-fold higher MS risk compared to non-smokers 
and non-carriers of HLA-DRB1*15:0136.  
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1.3 Epigenetics 
In the year of 1942 Waddington coined the term epigenetics as “changes that occur in the 
phenotype without altering the genotype” 37,38. 
Today epigenetics is described as the study of mechanisms that impact gene expression 
without changing the actual underlying DNA sequence39. DNA methylation, histone 
modifications, polycomb complexes and non-coding RNAs (ncRNAs) are the main studied 
epigenetic mechanisms that influence gene expression in a tissue and cell type specific 
manner40. Acquired epigenetic changes can be stably inherited through mitosis, but the extent 
of potential trangenerational inheritance in humans remains unknown. Environmental factors 
like diet, smoking or physical activity can induce epigenetic changes41,42,43, which are also 
under strong regulation by the genetic background44. Knowing that most of the known 
complex diseases result from an interplay between environment and genetics45 and that 
genetics only explains a part of disease risk (‘hidden heritability’) makes it tempting to 
speculate that epigenetic mechanisms can be the missing link in the etiology of these 
diseases. 
In this thesis we mainly studied genomic imprinting, a well-known epigenetic marking 
process that can cause parent-of-origin effects, and DNA methylation, a well-known 
epigenetic mechanism, in the context of MS and its animal model. 
1.3.1 Genomic Imprinting 
Genomic imprinting describes an epigenetic marking process that causes a gene to be 
expressed only from the maternally or paternally inherited chromosome46.  
The term Genomic Imprinting was first coined in the 1960s by Helen Crouse describing the 
elimination of paternally derived X chromosomes in sciarid flies47. In 1984, Solter and Surani 
delivered the defining experiments, demonstrating that in mammals not all genes are 
expressed from both inherited chromosomes in the same nucleus, but the underlying 
mechanisms remained still unknown48. Six years later the first imprinted genes, Igf2r, Igf2, 
H19, were identified49,50,51,52 and in 1993 Jaenisch and co-workers provided the first evidence 
for DNA methylation being one of the underlying epigenetic mechanisms in genomic 
imprinting53. Up to date approximately 150 imprinted genes in mice and 100 imprinted genes 
in humans have been identified and well established54,55,56,57.  
Imprinted genes tend to occur in clusters of 3-12 genes that can spread over 80 kb to 3.7 
Mb of DNA46 (Fig.1). All imprinted gene clusters contain a differentially methylated region 
(DMR) that partly controls the imprinting of the cluster and is therefore also described as 
the imprinting control region (ICR)58,59,60,61,62. Beside the ICR, long non-coding RNAs 
(lncRNAs)63,64,65 and insulators like the zinc finger protein CTCF66,67 associated with 
different imprinted clusters are also involved in the regulation of imprinting. Over-expression 
of these lncRNAs due to methylation changes in the ICR of imprinted gene clusters is a 
common feature for imprinting disorders like the Beckwith-Wiedemann syndrome68. This 
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indicates the importance of the interplay between ICR and lncRNAs for the regulation of 
imprinted mRNA genes in the clusters. Further, genomic imprinting can differ between 
individuals and change with age, tissue or even cell type suggesting diverse mechanisms of 
regulation56,57.   
 
Figure 1: Imprinted Dlk1-Dio3 locus on rat chromosome 6 
Imprinted genes have important functions in regulating fetal growth and development in 
mammals. Here, paternally expressed imprinted genes function as growth promoters 
whereas maternally expressed imprinted genes function as growth repressors46. Besides 
their role in development, several imprinted genes have been implicated in regulation of 
immune responses, including differentiation and activation of T and B lymphocytes that 
constitute the major cellular components of the adaptive immune response69.  
Why genomic imprinting evolved in mammals remains still under investigation but two 
attractive hypotheses are intensively discussed in the field:  
“Genomic Imprinting evolved in response to a parental conflict situation” by Moore and 
Haig 199170. 
The hypothesis by Moore and Haig is based on the opposite interests of the paternal and 
maternal genome. Namely, whereas paternally expressed imprinted genes are known to 
promote embryonic growth trying to maximize the chance for a single individual carrying a 
specific paternal genome, maternally expressed imprinted genes inhibit embryonic growth 
with the purpose to divide their genome to several embryos possibly carrying different 
paternal genomes.  
“Trophoblast defense” by Varmuza and Mann 199471. 
The “Trophoblast defense” hypothesis formulated by Varmuza and Mann in 1994 is on the 
contrary founded on the fact that the maternal genome allows for internal reproduction by 
females having the necessary anatomically requirement whereas males lack such an 
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anatomical equipment. Genomic Imprinting is therefore supposed to silence genes on the 
maternal chromosome that would increase placental growth or activate genes that 
counteract the process. 
Both hypotheses are not able to explain the full extent of data available on genomic 
imprinting72. 
Genomic imprinting is one of the best-characterized epigenetic mechanisms that cause 
parent-of-origin effects. The term parent-of-origin effect refers to the phenomenon in which a 
disease phenotype of the predisposing allele depends on the parental origin, i.e. on whether 
the allele was inherited maternally or paternally. Beside genomic imprinting, additional 
mechanisms causing parent-of-origin effects involve the sex chromosomes, mitochondria, 
gender transmission bias, and trans-generational effects (including maternal intrauterine 
effects and maternal-offspring interactions)73.  
1.3.2 DNA methylation  
“5mC as the 5th base of the genetic code” by David Allis74 . 
DNA methylation (5mC) is described as a mechanism where a methyl group (CH3) is added 
at the 5' position of the pyrimidine ring of the cytosine residues in CpG dinucleotides 
mediated by DNA methyltransferases (DNMTs).  
The actual existence of chemical modifications of DNA bases, like for instance the addition 
of a methyl group to a cytosine, was discovered in 194875.  Thirty years later Razin and Bird 
provided experimental evidence for the functional impact of DNA methylation on gene 
expression and the existence of CpG islands, respectively76,77. Studying the impact of 
methylation changes in the living cell became possible with the discovery of the nucleoside 
analogue, 5-azacytidine, which inhibits DNA methylation78. 
CpG islands (CGIs) describe the accumulation of CpG residues within a region of 1 kb that 
can occur upstream of promoters and in general appear unmethylated79. However, during the 
process of X chromosome inactivation in female mammals those unmethylated CpG islands 
become de novo methylated mediating the repression of gene transcription on the X 
chromosome undergoing inactivation80. De novo methylation is regulated by the methylation 
enzymes DNMT3A and DNMT3B81 and maintained by the methyltransferase DNMT182. 
Methylation occurring in promoter regions can lead, as described for the process of X 
chromosome inactivation, to repression of gene transcription, either by directly inhibiting 
the binding of transcription factors or indirectly by recruiting methyl CpG binding 
proteins83,84.  
DNA methylation is involved in general processes like the aforementioned processes of X 
chromosome inactivation, genome stability and genomic imprinting. However, DNA 
methylation also has a critical role in immune cell specific functions, like CD4+ T helper 
cell differentiation and T cell activation85,86,87,88.  Therefore alterations in DNA methylation, 
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triggered by environmental risk factors like smoking, or aging or genetic risk factors, might 
lead to aberrant CD4+ T cell function due to changes in gene expression but also incomplete 
X chromosome inactivation and disturbances in genomic imprinting.  
1.3.3 Histone modifications 
In the nucleus, 147 base pairs of DNA are wrapped around dimers of the histone proteins 
H2A, H2B, H3 and H4 forming the basic unit of chromatin, the nucleosome89.  
Tails of histone proteins, which are rich in arginine and lysine residues, are prone to 
posttranslational modifications that subsequently can lead to changes in gene expression90. 
Lysine acetylation and deacetylation of histone proteins associate with gene transcription and 
gene repression, respectively90. Enzymes catalyzing the process are known as histone 
acetyltransferases (HATs) and histone deacetylases (HDACs)91. Further, methylation of 
lysine residues mediated by histone lysine methyltranferases can associate with both gene 
transcription and repression90. The first histone lysine demethylase was discovered in 200492.  
Variation in the histone proteins H2A or H3 also allows for modification of the chromatin 
structure and is associated with processes like cell proliferation93 and CNS development94. 
1.3.4 Non-coding RNAs 
“80% of the genome is transcribing ncRNAs“, ENCODE95.  
Non-coding RNAs describe RNA transcripts that do not encode for proteins. With the 
invention of high throughput sequencing, evidence was provided for the existence of a higher 
number of genes that encode for non-coding transcripts than the number of genes for protein-
coding transcripts95.  
With the identification of messenger RNA (mRNA), transfer RNA (tRNA) and ribosomal 
RNA (rRNA), RNA was first believed to only act as a template for protein synthesis and that 
the increased number of non-coding transcripts were rather debris or noise than of functional 
importance96. 
However, there is emerging evidence for roles of ncRNAs including small RNAs like 
microRNAs (miRNAs) and longer non-coding transcripts (>200 nt) going far beyond the role 
of RNA first described.   
1.3.4.1 MicroRNAs 
MicroRNAs are non-coding RNAs that are short (20-23 nt), single stranded and processed 
from hair pin precursors. Their discovery in 1993 and their functional impact on gene 
regulation provided further evidence for RNAs being more than only a template for DNA97,98.  
Primary miRNA hairpins (pri-miRNA) are produced by RNA polymerase II and cleaved by a 
microprocessor complex containing the enzyme Drosha in the nucleus. After cleavage, 
Exportin 5 exports the pre-miRNA from the nucleus into the cytoplasm. Here, the enzyme 
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Dicer cleaves the pre-miRNA to its mature length, which results in the mature miRNA being 
loaded into the RNA induced silencing complex (RISC) together with Argonaute (AGO) 
proteins. By base pairing between the seed region (2-8 nucleotides at the 5’ end of the mature 
miRNA) of the miRNA and the 3’ untranslated region (3’UTR) of the target gene the mature 
miRNA guides the RISC to silence the target mRNA either by degradation, translational 
repression or deadenylation99.  
With their regulation of multiple target mRNAs100, miRNAs have been demonstrated to be 
involved in the regulation of many physiological, developmental and disease processes. 
Among other developmental processes miRNAs have been demonstrated to be crucial for the 
development of the immune system but also in particular for the innate and adaptive immune 
response101,102. In T and B cells impaired miRNA biogenesis leads to aberrations in their 
development and T helper cell differentiation102.  
1.3.4.2 Long non-coding RNAs 
Non-coding RNA transcripts that are more than 200 nt long are termed long non-coding 
RNAs (lncRNAs). According to their location in relation to protein coding genes lncRNAs 
are divided into antisense, intronic, overlapping and intergenic lncRNAs.  Their expression 
occurs in a stage- and tissue-specific manner making them good candidates to fine-tune the 
fate of different cells including T cells103. 
Genetic studies revealed lncRNAs such as Xist and Airn, to be involved in X inactivation and 
genomic imprinting, respectively, by regulating gene expression104,105. Different mechanisms 
have been described of how lncRNAs can interfere with gene expression. They can either (i) 
bind transcription factors, prohibiting them from binding to DNA, (ii) bind two or more 
proteins due to their tertiary structure, bring them into close proximity and guide them to 
DNA or (iii) result in chromosome looping similar to an enhancer like model103.  
1.3.5 Epigenetics and Multiple Sclerosis 
More and more evidence has been given for epigenetic mechanisms being the bridge between 
genetics and environment in the pathogenesis of MS and explaining the ‘hidden heritability’ 
in disease inheritance. 
Over the last years, accumulating evidence for parent-of-origin effects being involved in the 
etiology of MS has been provided. There is for instance a higher risk for maternal half-
siblings to develop MS compared to paternal siblings, implying a parent-of-origin 
involvement in MS development107. Further evidence was given when it was shown by Chao 
et al. that the most prominent MS risk gene, HLA-DRB1*15:01, is more likely to be 
transmitted from mother-to-daughter compared to from father-to-daughter108. One of the best- 
characterized epigenetic manifestations that mediate parent-of-origin effects is the 
aforementioned genomic imprinting. 
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In addition to the observed parent-of-origin effects, different studies were conducted to detect 
DNA methylation changes in MS disease and further strengthened a role for epigenetics in 
MS disease etiology. All studies described in this paragraph performed genome wide 
methylation analysis in case-control cohorts utilizing the 450K methylation array.  
In 2014, Graves et al. performed their analysis in CD4+ T cells and detected differences in 38 
regions with the most significant changes in the HLA-DRB1 region. Interestingly, most of the 
differences detected in non-HLA regions mapped to genes that were previously associated 
with MS. In a follow-up study from the same group in CD8+ T cells, a distinct set of 79 
differentially methylated CpGs was detected109,110.  
Bos et al. investigated CD4+ and CD8+ T cells and whole blood and detected differences in 
global methylation levels in CD8+ T cells but no genome-wide significant differences on a 
CpG level between cases and controls. This study further underlines the importance of 
purifying different cell types when performing genome-wide methylation analysis111.    
Another study performed by Huynh and colleagues uncovered subtle but significant and 
consistent changes when comparing normal appearing white matter between cases and 
controls. Several identified DMRs were related to oligodendrocyte genes or genes involved in 
oligodendrocyte survival112. 
Overall, the observed differences in methylation were rather subtle but consistent for all of 
these studies which stands in contrast to large differences often observed in cancer studies. 
Huynh et al. explained in their study this phenomenon with the complete disruption of the 
cell in cancer and provided evidence that these small changes were able to impact gene 
expression when they occurred in certain gene regions in other complex diseases. Recently, a 
complete review was released discussing subtle but consistent methylation changes as the 
hallmark of complex diseases113.  
A number of studies have also profiled miRNAs in MS patients114, comparing different 
conditions, miRNA sources and using different platforms. After initial modest overlap 
between different studies, several miRNAs are now emerging as important regulators in 
MS. There is also emerging evidence for miRNAs termed NeurimmiRs that are implicated 
in both neuronal and immune processes mediating possibly the crosstalk between the two 
systems. The miRNAs miR-155 and miR-326 have been demonstrated to be dysregulated 
in PBMCs and CD4+ T cells of MS patients and lead to an ameliorated EAE disease course 
when silenced. The same miRNAs were upregulated in active MS lesions in the brain90.  
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2 AIMS 
 
The low concordance rate of MS in monozygotic twins26,28, the fact that only a part of disease 
inheritance and variance can be explained by all identified MS risk genes18,29, the observed 
parent-of-origin effects107,108 and changes in DNA methylation between cases and controls114 
all strongly suggest a role for epigenetic mechanisms in MS etiology, but the extent of their 
contribution and the underlying mechanisms are far from being understood.  
In this thesis we set out to shed further light on how epigenetic mechanisms, in particular 
DNA methylation and ncRNAs, and their manifestations, such as genomic imprinting, impact 
the pathogenesis and inheritance of MS and its animal model.  
We focus on the role of epigenetic mechanisms in regulating CD4+ T cells functions due to 
the critical role of CD4+ T cells in the etiology and pathogenesis of MS and EAE, and 
adaptive immunity in general. 
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3 METHODOLOGICAL CONSIDERATIONS 
 
3.1 Epigenome-wide association studies in Multiple Sclerosis and 
its animal model 
Epigenetic mechanisms in MS were investigated in this thesis by conducting different 
epigenome-wide association studies (EWAS). We carried out EWAS both in its classical 
sense, by investigating changes in DNA methylation, and we also investigated the 
consequences of DNA methylation in the form of genomic imprinting. We here set out to 
explore the role of the epigenome in inheritance and pathogenesis of EAE by utilizing a 
reciprocal backcross design to explore parent-of-origin effects, which can be caused by 
genomic imprinting. Further, a next generation sequencing (NGS)-based approach was used 
to survey genomic imprinting in CD4+ T cells and to profile miRNAs at the initial stage of 
EAE development. With Illumina 450K, an array based technology, we studied genome-wide 
variation in DNA methylation in CD4+ T cells and monocytes of MS patients and controls. 
3.1.1 Using a reciprocal backcross design to identify parent-of-origin effects 
in MS-like disease 
We studied the impact of parent-of-origin on genetic regulation of MS-like autoimmunity 
using a well-established model of MS under controlled breeding and environmental 
conditions. To identify parent-of-origin dependent loci that predispose for EAE on a genome-
wide level, a reciprocal backcross between the EAE-susceptible DA and the MHC-identical 
EAE-resistant PVG rat strain was established (Fig.2). First an F1 generation was created by 
breeding DA females with PVG males (DAxPVG). Next we created two independent 
experimental populations, the DA backcross (DABC) population and the PVG backcross 
population (PVGBC) by breeding either DA rats with F1 hybrids or PVG rats with F1 
hybrids in a reciprocal manner. In detail, DA females were bred with F1 males (DAxF1) and 
F1 females were bred with DA males (F1xDA) in the DABC population. In the PVG 
backcross population, we bred PVG females with F1 males (PVGxF1) and F1 females with 
PVG males (F1xPVG). This breeding regiment resulted in genetically unique animals 
enabling linkage analysis, which identifies genomic regions where a particular allele tends to 
be inherited together with the disease phenotype, while being able to track the parental origin 
of inherited alleles. For instance, in the DABC population, PVG alleles are either exclusively 
paternally (DAxF1) or maternally (F1xDA) inherited, whereas in the PVGBC population, it is 
the DA alleles that are either paternally (PVGxF1) or maternally (F1xPVG) inherited 
depending on the reciprocal cross. Using the two reciprocal backcross populations, DABC 
and PVGBC, enabled validation of identified parent-of-origin dependent disease loci. 
 24 
 
Figure 2: Schematic overview of reciprocal backcross breeding 
3.1.2 Exploring the imprintome of CD4+ T cells and tissues: an RNA 
sequencing based approach 
The catalogue of imprinted genes in mice has been steadily increasing due to several studies 
that have been conducted in different tissues over the last years. With RNA sequencing 
becoming the method of choice to identify imprinted genes on a genome-wide level, several 
groups set out to quantitatively measure allele-specific expression in samples from reciprocal 
crosses of inbred mouse strains56,57. Allele-specific expression is quantified by counting reads 
with the reference allele as well as reads with the alternative allele using known single 
nucleotide variations (SNVs) to establish the parental origin of the allele. However, DeVaele 
et al. demonstrated in their validation study that this approach can also lead to a high rate of 
false positive findings due to an insufficiently robust statistical analysis, low number of 
biological replicates, mapping bias and a low library complexity115.  
In our study, we conducted RNA sequencing in rat reciprocal hybrids between the EAE-
susceptible DA rat strain and the EAE-resistant PVG rat strain and tried to take most of these 
considerations into account to provide a robust survey of imprinted genes in a so far 
unexplored data set of sorted CD4+ T cells and tissues in the rat. We employed large number 
of independent biological replicates (17 individuals per cross) and a starting amount of 1-2 µg 
of input RNA that should reduce low library complexity issues. We considered only 
independent SNVs (separated by a distance greater than the read length of 100 bp) that 
showed sufficient coverage of 24X in the initial genome-wide discovery and 10X when 
multiple consecutive SNVs where further investigated. Calling of imprinted genes was based 
on the true false discovery rate of 4 % (p < 10-7), the degree of allele specific bias with a 
previous identified cut-off of 65% and the validation using targeted sequencing in 
independent samples. Since recurrence of imprinting across related tissues has been reported, 
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we performed RNA sequencing in two immune tissues which enabled us to get further 
evidence for imprinted candidate genes identified in the CD4+ T cells. Additionally, unlike all 
other studies that sequenced poly-A containing RNAs, we sequenced all RNA species 
depleted of ribosomal RNA with retained strand information that allowed investigation of 
non-coding and/or antisense transcripts.  
3.1.3 Classical epigenome-wide association studies in Multiple Sclerosis: a 
450K DNA methylation approach in CD4+ T cells and monocytes  
Both of our methylation studies in MS were, as most of the EWAS studies up to date, 
conducted in a case-control cohort comprising individuals that are collected based on their 
phenotype i.e. MS cases at different stage of disease and healthy controls. Considering the 
history of disease with onset in adults and long disease duration, this is the most feasible type 
of a cohort to study. To detect methylation differences between cases and controls in CD4+ T 
cells and monocytes, we utilized widely-used Illumina 450K beadchip arrays, which detect 
485.000 CpG sites throughout the genome. Considering available DNA amount from sorted 
cells, costs and throughput, 450K arrays were the most practical way to detect methylation 
genome-wide. Moreover, as 450K arrays are widely used by other investigators, this enables 
comparison with other studies and gives a possibility to replicate our findings. For instance, 
we investigated our findings in the MIR21 locus in CD4+ T cells in two other MS case-
control cohorts from Norway and Australia. Having this data available improved the 
interpretability of our findings and enabled us to strengthen our hypotheses.  
3.2 VALIDATION APPROACHES 
Different technical and functional validation approaches were applied in this thesis. 
RNA sequencing approaches suffer from a high rate of false positive calls due to extensive 
data processing and statistical analysis, which makes validation in an independent sample 
cohort and with an independent method almost indispensable. We chose to validate our 
findings in an independent smaller sample cohort comprising three individuals per cross as 
biological replicates and one technical replicate to confirm known and potential novel 
imprinted genes. Out of selected candidate imprinted genes, 17 were validated giving a total 
validation rate of 77.3% (17/22). Additionally, we obtained further evidence by investigating 
several tissues, some functionally related, from the same individuals. 
The use of a transgenic mouse model expressing elevated levels of the imprinted Dlk1 gene 
enabled us to carry out a functional validation and confirm Dlk1 as a potential candidate gene 
mediating observed parent-of-origin effect in EAE. The functional importance of Dlk1 was 
shown by its involvement in the underlying immune responses, which also gave further 
insights into mechanisms of its function in disease. 
Since increased technical processing and complicated analysis pipelines can also be an issue 
in the analysis of Illumina 450K methylation data, we applied technical pyrosequencing 
validation of representative CpGs in both of our studies in MS. However, power is always an 
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issue in studies of complex and heterogeneous diseases such as MS. Therefore, we attempted 
to replicate our findings in independent cohorts. Additionally, when such cohorts or data 
types were not readily available, we tried to gain further support from analyzing additional 
omics data such as genome and transcriptome. This approach can provide additional 
functional interpretations of detected differences.  
Nevertheless, unlike genetic studies, there is always an issue of reverse causality in EWAS 
i.e. is the identified epigenetic change causing the phenotype or is it a consequence of the 
phenotype. We attempted to address this issue by investigating DNA methylation changes as 
a potential mediator of the genetic variation that causes disease. In addition, we utilized an 
invitro reporter system to confirm that a change in DNA methylation at a given locus has a 
potential to impact transcription of the locus. 
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4 RESULTS 
 
In the studies included in this thesis we set out to investigate if and how epigenetic 
mechanisms contribute to inheritance and pathogenesis of MS and its animal model EAE.  
4.1 Parent-of-origin affects susceptibility to EAE 
Several studies implicate epigenetic mechanisms in the inheritance of MS. For example, 
parent-of-origin effects have been detected in multigenerational MS studies107,108. The best-
characterized epigenetic mechanism that causes parent-of-origin effects is genomic 
imprinting which itself is regulated by one of the most-studied epigenetic mechanisms i.e. 
DNA methylation58,59,60,61,62. Thus, genomic imprinting may provide one explanation for the 
observed effects in MS. However, parent-of-origin effects are challenging to study in human 
population as large multigenerational cohorts are rarely available and potential environmental 
cofounders are difficult to account for. 
Therefore, in Study I we addressed the impact of parent-of-origin using a well-established 
model of MS that closely mimics human disease, and two controlled large reciprocal 
backcrosses between the strains with well-characterized genetic regulation of disease. We 
uncovered that 37% (6/16) and 54% (6/11) of all loci that were identified to predispose for 
EAE in the reciprocal backcross with the susceptible and resistant strain, respectively, depend 
on the parental origin of the disease predisposing allele. Several mechanisms may explain 
parent-of-origin effects; however, apart from the influence of the Y chromosome, we did not 
observe strong evidence for other genetic mechanisms. In contrast, the majority of parent-of-
origin dependent loci displayed effects resembling genomic imprinting suggesting 
involvement of epigenetic mechanisms. Of these, several overlapped well-known clusters of 
imprinted genes i.e. Gnas, Igf2r and Dlk1-Dio3, which contain members known to control 
immune functions and may mediate the effect of detected loci. For example, a locus on rat 
chromosome 6 was only associated with EAE when the disease-predisposing allele was 
paternally inherited, resembling an imprinting-like pattern (Fig.3). Interestingly, this locus 
overlaps a well-known imprinted cluster i.e. the Dlk1-Dio3 cluster. The fact that only Dlk1 
from the genes tested in the locus displayed a lower expression when the disease-
predisposing allele was paternally inherited and that it had been associated with autoimmune 
diseases before made it a good candidate gene to mediate the observed parent-of-origin effect 
on chromosome 6.  
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Figure 3: Detection of a parent-of-origin dependent EAE risk locus on rat chromosome 6 when the disease-
predisposing alleles were paternally inherited 
Taking into account parental origin enabled us to identify multiple novel loci that predispose 
for disease, while the majority of loci that did not depend on the parental origin has been 
previously reported. This study highlights the involvement of epigenetic mechanisms in the 
inheritance of MS-like disease and underlines how the incorporation of parent-of-origin into 
conventional studies can potentially lead to the identification of novel risk genes like the 
imprinted Dlk1 gene.  
4.2 Imprinted genes affect susceptibility to develop EAE and may 
control T cell function 
Beside their role in development, imprinted genes have become more and more implicated in 
the regulation of immune responses in inflammatory diseases. Due to our observations in 
Study I that the paternally inherited disease-predisposing allele in the Dlk1-Dio3 locus also 
predisposes for lower Dlk1 expression in the backcross rats, we speculated that paternally 
expressed Dlk1 gene may control susceptibility to EAE. Experiments conducted in trangenic 
mice expressing double dosage of Dlk1 compared to their wild type littermates revealed that 
reduced levels of Dlk1 drive more severe disease by modulating the T and B cell response in 
EAE and support our hypothesis that Dlk1 is at least partially responsible for the previous 
observed parent-of-origin effects on chromosome 6 (Fig.4).  
 
Figure 4: Ameliorated EAE disease course and modulated immune response, ex vivo and after restimulation 
with MOG antigen, in Dlk1 transgenic mice expressing elevated levels of Dlk1. 
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To identify additional imprinted genes that could potentially mediate the susceptibility to 
EAE, we conducted in Study II a genome-wide identification of genes that express parental 
allelic bias in CD4+ T cells, thymus, spleen and brain. By using an RNA sequencing based 
approach in reciprocal F1 hybrids we were able to identify and validate seven imprinted 
autosomal loci, six of them being well-known imprinted loci (Igf2r, Peg12, Kcnq1, Gnas, 
Zrsr1 and Impact) and one novel locus overlapping the cluster of C-type lectin receptors in 
CD4+ T cells (Fig.5). Imprinted genes in the C-type lectin receptors, Igf2r and Gnas clusters 
might mediate effects of the parent-of-origin EAE QTLs on chromosome 4, 1 and 3, 
respectively, identified in Study I. 
 
Figure 5: Identified known (A) and potential novel (B) imprinted loci on autosomes in CD4+ T cells from adult 
rat reciprocal hybrids. 
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We further observed that most of the imprinted genes located on autosomes including not yet 
annotated lncRNAs were preferentially paternally expressed. Those imprinted lncRNAs were 
detected in the well-known imprinted clusters of Igf2r and Kcnq1 on chromosome 1 and in 
the Gnas cluster on chromosome 3 likely representing lncRNAs Airn, Kcnq1ot1 and Gnas-
as1 (Nespas), known to associate with these clusters in other species116,117,118. In contrast to 
imprinted genes on the autosomes, imprinted transcripts on the X chromosome displayed 
preferential expression from the maternal allele, which we identified to be regulated by the 
parent-of-origin and genetic background in adult rats.  
While studying imprinting across several tissues and developmental stages, we demonstrated 
that (i) imprinting is tissue-specific and associates with tissue-specific lncRNAs, (ii) parental 
expression of imprinted genes may differ between the tissues and, most interestingly, (iii) 
there are novel candidate imprinted genes with well-known immune functions that are 
imprinted only in the brain and display a shift between parental alleles during early life. 
Our data from Study I and II demonstrate how imprinted Dlk1 interferes with the underlying 
immune response in MS-like disease by mediating changes in T and B cell activation and 
provide further insights into the underlying mechanisms on how parent-of-origin might 
impact the immune response by affecting CD4+ T cell function through genomic imprinting, 
lncRNAs and X inactivation skewing. At the same time we extend the catalogue of imprinted 
genes by a survey of imprinted genes in CD4+ T cells, thymus, spleen and brain in the rat. 
4.3 Non-coding RNAs as mediators of epigenetic mechanisms in 
EAE and MS 
The vast majority (90%) of the imprinted autosomal SNVs identified in CD4+ T cells in 
Study II that displayed strong paternal bias (96% expression from the paternal allele on 
average) belong to lncRNAs. Those imprinted lncRNAs have been associated with the 
regulation of genomic imprinting itself in cis116,117,118 but accumulating evidence also 
suggests a trans acting role for the imprinted lncRNAs119,120.  
Besides lncRNAs, clusters of small non-coding RNAs, including miRNAs, are also known to 
reside in imprinted loci. The largest cluster of imprinted miRNAs (including miR-127, miR-
434, miR-136, miR-379, miR-134, miR-541, miR-369) is located in the aforementioned 
Dlk1-Dio3 cluster (Fig.6) that we identified to be overlapping with a parent-of-origin EAE 
QTL on rat chromosome 6 in Study I. Indeed, we detected all of the imprinted miRNAs in 
this cluster to display higher expression in the susceptible strain during induction of EAE in 
Study III.  
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Figure 6: Expression of imprinted miRNAs in the well-known imprinted Dlk1-Dio3 cluster. 
In Study III we set out to characterize miRNAs that are involved in the early immune 
response in rats differing in their susceptibility to EAE. Overall we identified 544 miRNAs in 
the draining lymph nodes after EAE induction. Out of 329 miRNAs that could be reliably 
quantified, 43 miRNAs were differentially expressed between the strains. Most of the 
differentially expressed miRNAs (35) displayed higher expression in the susceptible strain 
whereas only eight miRNAs were higher expressed in the resistant strain. Only 1/3 of tested 
differentially expressed miRNAs showed also differential expression in naïve lymph nodes 
indicating that most of the regulated miRNAs are EAE dependent. Target genes of higher 
expressed miRNAs in both strains identified by using computational prediction tools and 
whole genome expression data revealed an involvement in functions that are important for 
MS and EAE like immune cell migration (Cxcr3) and cellular maintenance and signaling 
(Prkcd, Stat1). By far the most abundant was miR-21, a miRNA that has already been 
associated with autoimmune diseases121,122,123,124, and that showed higher expression in the 
susceptible DA strain during the initial stage of EAE.  
Interestingly, when investigating methylation in CD4+ T cells from MS patients in Study IV 
on a genome-wide level, we identified, among the most significant hits, multiple CpG probes 
that map to the last two exons of the VMP1 and the entire MIR21 gene on chromosome 17. 
Here, we observed a significantly higher methylation at all eleven consecutive CpG sites in 
RR-MS patients in relapse when compared to SP-MS patients and healthy controls (Fig.7). At 
the same time we demonstrated that the increased methylation levels associated with lower 
expression of mature miR-21, but not VMP1, in RR-MS patients supporting a functional 
impact of methylation levels on the expression of miR-21. Enrichment analysis for miR-21 
target genes, identified using RNA sequencing in CD4+ T cells, revealed that there was a 
significant overrepresentation of miR-21 target genes among the up-regulated genes in CD4+ 
T cells of RR-MS patients. 
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Figure 7. Hypermethylation at MIR-21 locus at all 11 consecutive CpGs on human chromosome 17.  
Overall, Study II, III and IV, strongly support involvement of ncRNAs, lncRNAs and 
miRNAs, in regulating immune responses occurring in EAE and MS and suggests another 
way of how epigenetic mechanisms and genomic imprinting can affect the immune responses 
through the regulation of miRNAs and their target genes. 
4.4 DNA methylation as a mediator of risk factors in MS disease 
In Study IV we described how the disease state impacts DNA methylation in CD4+ T cells at 
a specific locus, MIR21, and how this can affect the underlying immune response in MS. 
Using a similar approach we studied DNA methylation changes in monocytes from MS 
patients in Study V. Here we identified significant methylation changes at multiple CpG sites 
that mapped to the HLA-DRB1 gene on chromosome 6 with MS patients displaying lower 
methylation levels when compared to controls. Knowing that the primary HLA effect in MS 
is mediated by the HLA-DRB1*15:01 allele, which is the strongest genetic risk factor in MS, 
we performed analysis in carriers and non-carriers and observed significantly lower 
methylation levels for homozygous carriers when compared to heterozygous carriers or non-
carriers (Fig.8). We further demonstrated allele-specific hypomethylation of HLA-
DRB1*15:01 that associated with higher expression of the allele and contributed to an overall 
higher expression of HLA-DRB1 in the carriers. The identified differentially methylated 
region in HLA-DRB1 displayed methylation-sensitive promoter and enhancer capabilities in 
an invitro reporter system. 
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Figure 8: HLA-DR15:01-dependent hypomethylation at the HLA-DRB1 gene on human chromosome 6.  
We then set out to address a role for DNA methylation as a mediator of genetic risk in MS 
genome-wide by performing Causal Inference Test (CIT) in a cohort of MS cases (n=140) 
and healthy controls (n=139). We identified 50 single nulcleotide polymorphisms (SNPs), all 
of them being located in the extended HLA region, whose association with the disease was 
dependent on DNA methylation changes at seven DMRs, four of which overlapped DMR 
detected in HLA-DRB1 in monocytes. Most of them were shown to mediate disease risk of 
the HLA-DRB1*15:01 allele using conditional association analysis in a large cohort of MS 
cases (n=8172) and controls (n=13263). Interestingly, three SNPs still conferred disease risk 
after adjusting for all known MS associated alleles in the HLA locus representing potential 
novel risk gene(s). These data strongly support our hypothesis that DNA methylation 
mediates, in part, the effect from the HLA-DRB1*15:01, and potentially other gene(s) in the 
locus and ascribes a causal role of DNA methylation in MS development. Unlike the HLA, 
we could not demonstrate in Study IV a mediator role for DNA methylation for MS risk in 
the aforementioned MIR21 locus in CD4+ T cells under tested conditions.  
This study highlights the role of DNA methylation as a mediator of genetic risk in MS 
disease and provides further insights into how methylation interferes with the underlying 
immune responses in MS through the higher expression of the HLA-DRB1 gene encoding the 
HLA class II molecules that present antigen to CD4+ T cells.  
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5 DISCUSSION AND FUTURE DIRECTIONS 
 
Over the last years a growing body of evidence suggests involvement of epigenetic 
mechanisms in the pathogenesis of complex diseases and our data contribute such evidence in 
Multiple Sclerosis.   
5.1 Epigenetic mechanisms of imprinted genes modulate 
pathogenesis of complex inflammatory diseases 
We demonstrate that more than 30% of genomic loci that predispose for EAE between the 
DA and PVG rat strains depend on the parental origin of the disease-predisposing allele. This 
implicates significant parent-of-origin effects in the animal model of MS supporting 
previously suggested effects in MS107,108. A pattern of identified parent-of-origin effects 
further suggests that epigenetic mechanisms controlling genomic imprinting modulate 
pathogenesis of EAE. 
Taking into account parental origin led to identification of novel risk loci, several of which 
overlap well-known clusters of imprinted genes, increasing our knowledge of 
immunopathogenic mechanisms in EAE. The exclusively maternally expressed Igf2r gene, 
which we showed to be maternally expressed in CD4+ T cells in rats after EAE induction, has 
previously been shown to be involved in T cell activation125 and could potentially mediate the 
observed effect of the locus on chromosome 1. We provide further evidence supporting the 
role of paternally expressed Dlk1 gene in mediating effects of the locus on chromosome 6. In 
inbred and backcross rats, we demonstrate that the paternally inherited risk allele predisposes 
for lower Dlk1 expression. In transgenic mice, we confirmed that lower Dlk1 expression 
leads to more severe disease and modified T and B cell responses. Dlk1 is known to inhibit 
Notch signaling by acting as a Notch antagonist126. In line with our results, previous studies 
have shown that the inhibition of Notch signaling can lead to no or less severe EAE in 
mice127. Further, increased Notch signaling has been shown to enhance T cell proliferation128 
and to prevent activated T cells from entering apoptosis129. Additionally, we provide evidence 
for a novel cluster of imprinted genes in CD4+ T cells, comprising C-type lectin receptors, 
which might mediate the effect of the locus on chromosome 4. We validated paternally 
expressed Klrc1, which is in proximity of the previously reported imprinted Klrb1f130 gene, 
further strengthening its imprinting status since novel imprinted genes tend to appear in 
regions that have already been identified as imprinted and may rely on already existing 
mechanisms of regulation. In addition to Klrc1, there are potentially several other C-type 
lectin receptors in the locus e.g. maternally expressed Klrc2, which were also detected in 
immune tissues from adult rats. C-type lectin receptors are expressed predominantly on the 
surface of NK cells but also CD4+ T cells and have been shown to regulate adaptive immune 
responses131,132,133 and potentially cause direct damage in MS134. 
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All together our data suggest that imprinted genes may modulate immune responses relevant 
for development of EAE and MS, in particular function of CD4+ T cells. What is the exact 
role of genomic imprinting, which is restricted to a small set of genes and has its main 
functions in early development, in controlling the immune system and susceptibility to 
inflammatory diseases, remains to be established. A loss of imprinting at the IGF2 locus, 
leading to an increased expression of IGF2, has been observed invitro after stimulation of 
naïve T cells79. In Rheumatoid Arthritis patients, loss of IGF2 imprinting relates to the degree 
of inflammation and leads to an enhanced cell growth and proliferation mediated by 
increased IGF2 expression in synovial fluid cells135. Both observations suggest that an 
inflammatory environment, which also exists in the lymph nodes and CNS in EAE and MS, 
can influence the imprinting status and expression of imprinted genes. Furthermore, Wang et 
al. demonstrated biallelic expression of genes related to the immune system located in one of 
the biggest clusters of imprinted genes, the X chromosome, in T cells from patients with 
systemic lupus erythematosus136. It is tempting to speculate that inflammatory stimuli, as well 
as other factors, may interfere with proper epigenetic regulation of imprinting and increase 
expression of imprinted genes which in turn may lead to increased cellular growth and 
proliferation contributing to chronic inflammation. Additionally, the intact imprinting status 
will dictate what alleles are being expressed, which may lead to alternative outcomes when 
the risk alleles are considered. The existence of imprinted gene networks (IGNs) comprising 
not only imprinted genes but also biallelic genes further adds to the complexity of how 
imprinted genes can impact immune responses. The IGN investigated by Al-Adhami and 
colleagues was identified to be involved in the control of the cellular composition of the extra 
cellular matrix, which impacts both T cell migration in inflamed tissue137 and differentiation 
of oligodendrocyte precursor cells into mature oligodendrocytes (unpublished data Bachelor 
thesis), both important functions involved in the pathogenesis of EAE and MS.  
Taken together, our data highlight the importance of incorporating parent-of-origin effects 
and allelic expression bias in conventional genetic and genomic studies in the future. This 
might address, at least in part, the issue of ‘hidden heritability’ and lead to the 
identification of novel MS risk genes. It may also facilitate characterization of the 
molecular mechanisms of such risk genes increasing our knowledge of pathogenic 
mechanisms.  
Imprinted miRNAs also reside in well-known imprinted gene clusters and these miRNAs 
have a potential to regulate genes related to MS and other inflammatory diseases. The largest 
cluster of imprinted maternally expressed miRNAs is located in the aforementioned Dlk1-
Dio3 cluster that we identified to overlap the parent-of-origin EAE locus on rat chromosome 
6. Several miRNAs from this cluster have been predicted to target the major MS risk gene, 
HLA-DRB1138. This may provide a mechanistic explanation for previously reported parent-of-
origin effects mapping to the HLA-DRB1 locus in MS108. However, no miRNAs have been 
experimentally shown yet to target HLA-DRB1 and this hypothesis needs further 
investigation. Additionally, pathway analysis performed on predicted targets of miRNAs 
located in the imprinted Dlk1-Dio3 locus reveal functions like T cell proliferation and T cell 
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activation, both crucial processes during the early immune response in EAE and MS138. We 
found that several of these miRNAs show higher expression in the EAE-susceptible strain 
compared to the EAE-resistant strain during early stages of EAE induction. This suggests a 
role for imprinted miRNAs, besides Dlk1, in mediating the observed parent-of-origin effect in 
the locus. Changes in miRNA expression due to loss of imprinting at ICRs have been 
implicated in complex diseases139. 
Interestingly, the majority of autosomal imprinted transcripts in CD4+ T cells exerted strong 
paternal expression bias. Among them we uncovered previously not annotated paternally 
expressed antisense lncRNAs, Airn, Kcnq1ot1 and Gnas-as1 in the rat located in the Igf2r, 
Kcnq1 and Gnas cluster, respectively. Besides their role in regulating gene expression in 
cis116,117, accumulating evidence suggests that lncRNAs can exert their repressive function 
also in trans forming aforementioned functional IGNs in different tissues and cells. For 
instance, H19, a lncRNA in the Igf2/H19 locus, has been shown to control embryonic growth 
through regulation of IGN of imprinted genes in trans119. It is tempting to speculate that 
paternal lncRNAs in CD4+ T cells may engage in interaction with a large number of genes in 
trans to control T cell functions. This is further supported by the observation in reciprocal F1 
hybrids showing that paternally transmitted susceptible alleles confer activation of several 
signaling pathways resulting in higher proliferation of CD4+ T cells. 
Very little is still known about the action of lncRNAs. To investigate potential targets of the 
imprinted lncRNAs in trans and how they impact T cell function, so called guilt by 
association studies need to be performed. The bioinformatics methods allow for the 
identification of lncRNAs and protein-coding genes that are tightly co-regulated140. In that 
way known functions of the protein-coding genes provide hints for the functions of the 
lncRNA of interest. However, to fully investigate the function of a lncRNA, gain and loss of 
function studies need to be performed similar to studies by Stelzer et al. done on the IPW 
lncRNA120.  
Investigation of different classes of ncRNAs may reveal novel mechanisms of the control of 
immune responses and inflammatory diseases. This can provide in the future basis for 
novel interventions targeting cell type specific networks of genes using RNA-based 
therapeutics141. 
5.2 Epigenetic mechanisms control immune reactions in MS 
To get further insights into immunopathogenic processes in MS we studied DNA 
methylation, which can actively impact gene regulation on the transcriptional level or be a 
marker of the genome activity142, in CD4+ T cells and monocytes from MS patients.  
In CD4+ T cells from MS patients we detected no genome-wide significant changes in DNA 
methylation. However, we observed subtle but significantly higher methylation changes at 
eleven consecutive CpG sites covering a locus encoding the MIR21 gene in RR-MS patients 
in remission compared to SP-MS patients and healthy controls. It is important to keep in 
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mind that the bulk of the CD4+ T cell population comprising different CD4+ T cell subsets 
was investigated. This could be a reason for the lack of genome-wide significant changes as 
potentially only a minor fraction of ‘pathogenic’ T cells might carry epigenetic differences. In 
addition, observed results could just represent differences in the cellular composition of the 
CD4+ T cell subsets between patients and controls. However, considering that it has been 
shown that MIR21 is hypomethylated in Th1/Th2143 and Tregs144 compared to naïve T cells 
and that miR-21 expression is the lowest in naïve CD4+ T cells compared to other CD4+ 
subsets145, the observed hypermethylation of MIR21 is less likely caused by differences in 
cell frequencies. Moreover, increased methylation levels at the MIR21 locus strongly 
associated with lower expression of mature miR-21 in RR-MS patients implying a functional 
impact of DNA methylation on the expression of miR-21. Additionally, enrichment analysis 
for miR-21 target genes revealed that there was a significant overrepresentation of miR-21 
target genes among the up-regulated genes in CD4+ T cells of RR-MS patients, irrespective of 
the target prediction tool or enrichment analysis method. Most of the mRNA targets of miR-
21 in CD4+ T cells have been shown to be involved in processes with a possible anti-
apoptotic and pro-proliferative effect, which stands in contrast to the rather pro-apoptotic role 
of miR-21 observed in cancer and other autoimmune diseases146,122,123,124. However, in most 
of these studies investigations were focused on a single mRNA target of miR-21, whereas it 
is well documented that a single miRNA tends to target multiple, often functionally related 
genes.  
Elevated levels of miR-21 in heterogeneous tissues represent a sign of inflammation but the 
exact roles of miR-21 in different immune cells and conditions are still under investigation. 
This is similar to findings from EAE by us and others147,148 showing up-regulation of miR-21 
during EAE induction and a significantly higher expression in the EAE-susceptible strain. In 
MS, miR-21 expression has also been reported to be up-regulated during the relapse phase in 
PBMCs from RR-MS patients when compared to SP-MS patients and controls149. In line with 
these findings, deletion of MIR21 in mice leads to protection from EAE121. This is in contrast 
to our observations of hypermethylation and lower expression of miR-21 in CD4+ T cells of 
RR-MS. Similar to our findings in RR-MS in remission, miR-21 expression was reported to 
be down-regulated in PBMCs during remission in RR-MS patients compared to controls150. 
Therefore, miR-21 seems to play different roles at different stages of disease depending for 
instance on the specific CD4+ T cell subset and the availability of its target genes. In regard to 
T cells a different expression pattern for miR-21 has even been observed for different CD4+ T 
cell subsets145. To fully investigate the function of this highly abundant miRNA well-
powered cohorts and pure cell subtypes will be needed, accompanied by functional 
investigations using for example inducible conditional MIR21 deletion models in mice. 
In monocytes from MS patients, we uncovered the most significant changes, encompassing a 
large number of CpG sites, in the HLA locus and specifically in the region encompassing 
exon 2 and surrounding intronic sequences of the HLA-DRB1 gene. The HLA-DRB1 locus 
has been denoted as the strongest genetic association to MS for more than 40 years now. 
Accordingly, we found that the major risk haplotype i.e. the HLA-DRB1*15:01 is 
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hypomethylated and predominantly expressed compared to several other tested haplotypes, 
contributing to overall higher expression levels of HLA-DRB1 in the carriers of the risk 
haplotype. These observations strongly suggested that, together with the structural 
characteristics of the peptide binding groove, HLA-DRB1 expression levels are most likely 
the so far missing co-mediator of the HLA-DRB1*15:01 risk haplotype. Indeed, recent studies 
have pointed to a relationship between HLA-DRB1*15:01 and the levels of HLA-DRB1 
expression151,152,153. Our data further suggest that this effect is mediated though DNA 
methylation. To support this hypothesis, we demonstrated that there is a strong negative 
correlation between DNA methylation in the locus and expression of HLA-DRB1 in 
monocytes, and that 5-aza treatment of PBMCs leads to higher expression of HLA-DRB1. 
Additionally, using an invitro reporter system, we demonstrated that the identified locus can 
act in a methylation-sensitive manner as an enhancer or a promoter. In line with our findings 
other recent studies investigating the interaction between the genome and epigenome in 
immune diseases and food allergy have found association with genetic variants and DNA 
methylation mapping to multiple loci in the HLA class II region154,155,156. To further 
strengthen the causal role of DNA methylation in causing disease, we performed CIT in a 
case-control cohort, followed by association analysis conditioning on the known MS risk 
variants. The majority of significant SNPs identified by CIT conferred the risk from HLA-
DRB1*15:01, strongly supporting DNA methylation as a mediator of the risk. Interestingly, 
five SNPs still showed evidence of association after adjusting for all known MS associated 
variants suggesting novel, methylation-dependent, associations in the HLA locus. None of 
these SNPs has been previously independently associated with the risk of developing MS and 
they require replication in independent materials.  
Our data in monocytes strongly suggest that genetic variation predisposes for different DNA 
methylation levels in the HLA-DRB1 locus. However, we could not establish what confers 
differences in DNA methylation in the MIR21 locus in CD4+ T cells. We attempted to test the 
influence of genetic variation in this locus, also known to associate with MS29 but found no 
evidence under tested conditions. Smoking, a well-known environmental factor in MS35, also 
known to induce changes in DNA methylation42, had no effect on either HLA-DRB1 or 
MIR21 methylation. We speculate that inflammation itself may trigger DNA methylation in 
MIR21, based on the observed hypermethylation in RR-MS and inflammatory neurological 
disease controls as well as association with inflammatory markers. Inflammation-induced 
methylation may form a feed-back loop in miR-21 regulation, which is a common 
mechanism of action of miRNAs, and in this case additionally controlled by epigenetic 
mechanisms. That this locus is prone to epigenetic regulation can be observed in several other 
diseases that report methylation changes. 
Our data demonstrate how DNA methylation can act as a co-mediator of MS risk gene by 
regulating the expression of HLA class II molecules in APCs, which in turn may modulate 
activation of CD4+ T cells. Additional epigenetic changes in CD4+ T cells, potentially 
triggered by inflammation itself, may further modulate their function in disease. These 
studies also exemplify how the integration of genome and epigenome data can lead to the 
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identification of so far not appreciated risk variants and form a basis for their further 
functional investigations. Importantly, identification of epigenetic changes that cause 
inflammatory disease or contribute to disease progression may open up for future 
therapeutic interventions based on targeting disease epigenome. 
5.3 Important considerations 
Considering our own experience and EWAS performed by others in the field, the following 
general aspects should be taken into account to increase the interpretability of future 
epigenetic studies in MS and other diseases with similar complex etiologies.  
A discovery cohort with appropriate size should be selected that provides sufficient power to 
test the hypothesis of interest. Clinical and lifestyle information for participants should be 
acquired to correlate epigenetic data with clinical parameters, treatment status and potential 
environmental risk factors but also to allow for the selection of a replication cohort that is 
similar to the discovery cohort.  
The cell type of interest should be purified to exclude that observed changes in an epigenetic 
mark occur due to differences in frequency of cell subsets or that prominent changes in a 
specific cell subset disappear in the bulk of the overall cell population. With even single cells 
displaying a different methylome epigenetic studies conducted on a single-cell level should 
be considered in the future.  
Analyses of epigenome-wide studies should be conducted using standardized pipelines to 
allow for data replication in independent sample cohorts from different laboratories.  
Methods that provide better genome-wide coverage should be considered. Ideally, full 
genome studies should be performed using for example whole genome bisulfite sequencing. 
This is especially relevant as we still do not know where in the genome cell type- or disease-
relevant epigenetic changes occur. This might be, however, difficult in large cohorts, 
primarily due to high costs and intensive analysis load, but feasible and better alternatives to 
450K are emerging. For example, lllumina has recently released the EPIC bead chip, which 
comprises 90% of 450K probes with additional coverage of enhancer regions. 
Additional epigenetic marks should be considered in future studies as DNA methylation 
represents only one of the mechanisms of epigenetic regulation. In that respect, it is also 
important to consider that the most widely used approaches to study DNA methylation based 
on bisulfite treatment do not distinguish between 5-methylcytosine and 5-
hydroxymethylcytosine, which might have different functional impact on gene regulation158. 
Addition of further omics data, especially genome and transcriptome, should accompany 
epigenome studies to allow for a better interpretability of observed changes in epigenetic 
marks, including novel statistical and bioinformatics tools to integrate multi-omics data.  
Finally, it is extremely relevant to establish the causality of identified epigenetic changes. 
With the recent advent of epigenome-targeting using for instance CRISPR/dCas9 fused with 
 40 
catalytic domains of epigenetic modifiers159, it might be possible in the future to directly 
assess the impact of an epigenetic change in a relevant cell type.  
Collectively, I hope that my work has provided a better understanding of how epigenetic 
mechanisms contribute to the pathogenesis of MS, and complex diseases in general, and 
further insights into factors that need to be considered in future studies. 
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